WHAT IS CLAIMED IS:

1. A tablet for oral administration comprising: (a) a core comprising deferiprone in a therapeutically effective amount and an enteric polymer; and (b) an enteric coating comprising an enteric polymer.

2. The tablet according to claim 1, wherein the enteric polymer in the core is selected from the group consisting of hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose (HPMC) phthalate, polyvinyl acetate phthalate, methacrylic acid copolymers, a derivative thereof, and a combination thereof.

3. The tablet according to claim 2, wherein the enteric polymer is present in an amount of 1% to 20% by weight of the core.

4. The tablet according to any one of claims 1 to 3, wherein the enteric polymer in the enteric coating is selected from the group consisting of hydroxypropyl methylcellulose acetate succinate (HPMCAS), HPMC phthalate, polyvinyl acetate phthalate, methacrylic acid copolymers, a derivative thereof, and a combination thereof.

5. The tablet according to any one of claims 1 to 4, wherein the core further comprises a basic excipient and a glidant.

6. The tablet according to claim 5, wherein the basic excipient is selected from the group consisting of meglumine, metal oxides, metal hydroxides, basic salts of weak acids, and a combination thereof.

7. The tablet according to claim 5 or 6, wherein the glidant is colloidal silicon dioxide.

8. The tablet according to any one of claims 5 to 7 further comprising a lubricant.

9. The tablet according to claim 8, wherein the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, talc, and a combination thereof.

10. The tablet according to any one of claims 3 to 9, wherein the enteric coating further comprises a plasticizer and an anti-tacking agent.

11. The tablet according to claim 10, wherein the plasticizer is selected from the group consisting of a citrate ester, diethyl phthalate, polyethylene glycol, glycerol, acetylated glycerides, acetylated citrate esters, dibutyl sebecate, castor oil, and a combination thereof.

12. The tablet according to claim 10 or 11, wherein the anti-tacking agent is talc.

13. The tablet according to any one of claims 1 to 12, wherein said core comprises 600 mg or 1000 mg of deferiprone.

14. The tablet according to claim 1, wherein said core comprises 600 mg or 1000 mg of deferiprone, an enteric polymer, a pH adjusting agent, a glidant, and a lubricant; and said coating comprises a plasticizer, an anti-tacking agent, an enteric polymer, and optionally a diluent.

15. The tablet according to claim 1, wherein said core comprises 600 or 1000 mg of deferiprone, HPMCAS-LF, Magnesium oxide, Colloidal Silicon Dioxide, and Magnesium stearate; and said coating comprises Triethyl Citrate, Talc, Methacrylic Acid Copolymer Dispersion, and optionally Sucrose.

16. The tablet according to any one of claims 1 to 15, wherein deferiprone is present in an amount comprised between 75 and 95% of the total core weight.

17. The tablet according to any one of claims 1 to 16 for use in a method for the treatment of iron overload in a subject, wherein said tablet is administered orally.

18. The tablet according to any one of claims 1 to 16 for use according to claim 17, wherein the subject with iron overload suffers from a disease selected from thalassemia, myelodysplasia and sickle cell disease.

19. The tablet according to any one of claims 1 to 16 for use according to claim 17, wherein said iron overload is transfusional iron overload.

20. The tablet according to any one of claims 1 to 16 for use according to claim 19, wherein the prior chelation therapy of said subject is inadequate.

21. The tablet according to any one of claims 1 to 16 for use according to claim 17, wherein the subject suffers from transfusional iron overload and has a cardiac MRI T2* of 20 ms or less.

22. The tablet according to any one of claims 1 to 16 for use according to any one of claims 17 to 21, wherein said tablet is administered twice a day.

23. A method for making a tablet according to any one of claims 1 to 16 comprising (a) mixing deferiprone and one or more excipients; (b) compressing the mixture of (a) into a tablet core; and (c) coating the tablet core with an enteric coating suspension or solution.